New York, NY -- (SBWIRE) -- 01/16/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: United Microelectronics Corp (ADR) (NYSE:UMC), CytRx Corporation (NASDAQ:CYTR), Orexigen Therapeutics, Inc (NASDAQ:OREX), Glu Mobile Inc (NASDAQ:GLUU)
United Microelectronics Corp (ADR) (NYSE:UMC) showed a volume of 2.52 million shares by the end of last trade whereas the average volume of the stock remained 1.12 million shares. The stock opened the session at $2.11 but then moved to $2.12. At that price, the stock showed a positive performance of 0.95%. United Microelectronics Corp. is principally engaged in the manufacturing of semiconductor products. The Company operates its businesses primarily through wafer production services. The Company provides the customer-tailored design, testing and production of silicon intellectual property (IP) products, embedded integrated circuits (ICs), masks and wafers.
Will UMC Continue To Move Higher? Find Out Here
CytRx Corporation (NASDAQ:CYTR) opened the session at $7.32 and closed the session at $6.91. The stock showed a negative performance of -5.86% in previous trading session. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS.
Has CYTR Found The Bottom And Ready To Gain Momentum? Find Out Here
Orexigen Therapeutics, Inc (NASDAQ:OREX) opened the session at $6.53 and closed the session at $6.76. The stock showed a positive performance of 3.36% in previous trading session. Traded with volume of 2.50 million shares in the prior session and the average volume of the stock remained 2.93 million shares. The beta of the stock remained 2.11. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Why Should Investors Buy OREX After The Recent Gain? Just Go Here and Find Out
Glu Mobile Inc (NASDAQ:GLUU) the stock decreased -0.25% and finished the session at $4.04. Traded with volume of 2.49 million shares in the prior session and the average volume of the stock remained 2.75 million shares. The beta of the stock remained 1.73. Glu Mobile Inc. (Glu) designs, markets and sells mobile games. The Company has developed and published a portfolio of action/adventure and casual games designed to appeal to a cross section of the users of smartphones and tablet devices who purchase its games through direct-to-consumer digital storefronts, as well as users of feature phones served by wireless carriers and other distributors.
Will GLUU Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)